133 related articles for article (PubMed ID: 16894114)
1. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study.
Bower JH; Maraganore DM; Peterson BJ; Ahlskog JE; Rocca WA
Neurology; 2006 Aug; 67(3):494-6. PubMed ID: 16894114
[TBL] [Abstract][Full Text] [Related]
2. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease.
Hancock DB; Martin ER; Stajich JM; Jewett R; Stacy MA; Scott BL; Vance JM; Scott WK
Arch Neurol; 2007 Apr; 64(4):576-80. PubMed ID: 17420321
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.
Whitton PS
Curr Opin Investig Drugs; 2010 Jul; 11(7):788-94. PubMed ID: 20571974
[TBL] [Abstract][Full Text] [Related]
4. Statin use and the risk of Parkinson disease: a nested case control study.
Samii A; Carleton BC; Etminan M
J Clin Neurosci; 2008 Nov; 15(11):1272-3. PubMed ID: 18823780
[TBL] [Abstract][Full Text] [Related]
5. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.
Bornebroek M; de Lau LM; Haag MD; Koudstaal PJ; Hofman A; Stricker BH; Breteler MM
Neuroepidemiology; 2007; 28(4):193-6. PubMed ID: 17851257
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-associated protein tau (MAPT) influences the risk of Parkinson's disease among Indians.
Das G; Misra AK; Das SK; Ray K; Ray J
Neurosci Lett; 2009 Aug; 460(1):16-20. PubMed ID: 19450659
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory drug use and age-related macular degeneration.
Swanson MW; McGwin G
Optom Vis Sci; 2008 Oct; 85(10):947-50. PubMed ID: 18832975
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study.
Etminan M; Carleton BC; Samii A
J Clin Neurosci; 2008 May; 15(5):576-7. PubMed ID: 18343119
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticosteroids associated with a decreased risk of psychosis.
Laan W; Smeets H; de Wit NJ; Kahn RS; Grobbee DE; Burger H
J Clin Psychopharmacol; 2009 Jun; 29(3):288-90. PubMed ID: 19440085
[TBL] [Abstract][Full Text] [Related]
10. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. A case-control study.
Ranka S; Gee JM; Johnson IT; Skinner J; Hart AR; Rhodes M
Digestion; 2006; 74(2):109-15. PubMed ID: 17167266
[TBL] [Abstract][Full Text] [Related]
11. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
12. Role of inflammation in the pathogenesis of Parkinson's disease: models, mechanisms, and therapeutic interventions.
Hong JS
Ann N Y Acad Sci; 2005 Aug; 1053():151-2. PubMed ID: 16179518
[No Abstract] [Full Text] [Related]
13. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF
Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473
[TBL] [Abstract][Full Text] [Related]
14. Neuroinflammation and Parkinson disease: the silent battleground.
Pfeiffer RF
Neurology; 2009 Nov; 73(18):1434-5. PubMed ID: 19812378
[No Abstract] [Full Text] [Related]
15. Number of children and risk of Parkinson's disease.
Frigerio R; Breteler MM; de Lau LM; Sanft KR; Bower JH; Ahlskog JE; Grossardt BR; ; Maraganore DM; Rocca WA
Mov Disord; 2007 Apr; 22(5):632-9. PubMed ID: 17265462
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood markers of oxidative stress in Parkinson's disease.
Younes-Mhenni S; Frih-Ayed M; Kerkeni A; Bost M; Chazot G
Eur Neurol; 2007; 58(2):78-83. PubMed ID: 17565220
[TBL] [Abstract][Full Text] [Related]
17. CARD15 variants in patients with sporadic Parkinson's disease.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Juzwiak S; Kurzawski G; Tan EK; Drozdzik M
Neurosci Res; 2007 Mar; 57(3):473-6. PubMed ID: 17174426
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
19. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease.
Rentzos M; Nikolaou C; Andreadou E; Paraskevas GP; Rombos A; Zoga M; Tsoutsou A; Boufidou F; Kapaki E; Vassilopoulos D
Acta Neurol Scand; 2007 Dec; 116(6):374-9. PubMed ID: 17986095
[TBL] [Abstract][Full Text] [Related]
20. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals.
Song IU; Kim JS; Chung SW; Lee KS
Eur Neurol; 2009; 62(2):99-104. PubMed ID: 19521085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
